SMITH JAMES C 4

What Happened

• James C. Smith, a director of Pfizer Inc., was granted 1,664.201 phantom share units on March 27, 2026. The units were valued at $27.04 each, totaling approximately $45,000. The transaction is reported as an award/acquisition (code A) and is a derivative grant rather than an open-market purchase.

Key Details

• Transaction date and price: 2026-03-27 at $27.04 per unit; total value ~$45,000.
• Quantity: 1,664.201 units (each unit = one phantom share of common stock).
• Shares owned after transaction: Not disclosed in this filing.
• Filing date: March 30, 2026 — reported within the standard SEC Form 4 reporting window.
• Footnotes: F1 — each unit equals one phantom share; F2 — these units are deferred director compensation (including dividend equivalents) that will be settled in cash or common stock at the director’s election following retirement from the Board.

Context

• This was a routine director compensation award (derivative/phantom-share units) rather than a purchase or sale in the open market. Such grants are commonly used to compensate directors and may be settled in cash or stock at a later date; they do not necessarily signal a near-term trading decision.